Share Price and Basic Stock Data
Last Updated: January 8, 2026, 7:05 am
| PEG Ratio | -5.39 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gufic BioSciences Ltd operates in the pharmaceuticals industry, focusing on the production and distribution of pharmaceutical formulations. As of September 2023, the company’s stock price stood at ₹332, with a market capitalization of ₹3,337 Cr. Revenue trends have shown a steady increase, with sales for the quarter ending September 2023 reported at ₹215 Cr, marking a significant rise from ₹175 Cr in September 2022. This upward trajectory continued with sales reaching ₹202 Cr in December 2023, and projected to trend higher in subsequent quarters. For the financial year ending March 2025, the company recorded total sales of ₹820 Cr, reflecting a consistent growth pattern compared to ₹691 Cr in March 2023. The trailing twelve months (TTM) sales totaled ₹870 Cr, indicating strong operational performance and a resilient market presence. This growth in sales underscores Gufic BioSciences’ strategic positioning within the competitive pharmaceutical landscape.
Profitability and Efficiency Metrics
Gufic BioSciences has demonstrated solid profitability metrics, with a reported net profit of ₹54 Cr and a net profit margin of 8.49% for the fiscal year ending March 2025. The operating profit margin (OPM) stood at 17.04%, indicating effective cost management despite rising expenses, which reached ₹683 Cr for the same period. The company’s return on equity (ROE) was reported at 12.3%, while the return on capital employed (ROCE) was 13.2%, reflecting efficient utilization of capital. However, the interest coverage ratio (ICR) was recorded at 5.70x, suggesting that while the company can cover its interest obligations, there is a potential concern regarding rising debt levels, which stood at ₹369 Cr. The cash conversion cycle (CCC) was notably high at 197 days, indicating that the company’s operational efficiency may be hampered by extended debtor and inventory days, which were 140 and 211, respectively.
Balance Sheet Strength and Financial Ratios
Gufic BioSciences’ balance sheet reflects a robust financial structure, with total assets reported at ₹1,170 Cr as of March 2025. The company’s reserves have increased to ₹619 Cr, demonstrating a strong retained earnings position. With borrowings at ₹369 Cr, the total debt-to-equity ratio stood at 0.51, indicating a moderate level of financial leverage. The book value per share increased to ₹59.94, suggesting a strengthening equity position. The interest coverage ratio of 5.70x allows for a comfortable margin in servicing debt obligations. However, the current ratio of 1.61 and quick ratio of 1.05 indicate a reasonable liquidity position, although close to the threshold of concern. The company’s price-to-book value (P/BV) ratio stood at 5.61x, which is relatively high compared to the sector average, suggesting that the stock may be overvalued or reflecting strong growth expectations.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Gufic BioSciences indicates a strong promoter holding of 72.50%, which reflects confidence from the founders in the company’s future. Foreign institutional investors (FIIs) hold a mere 0.33%, while domestic institutional investors (DIIs) account for 3.66%. Public shareholders comprise 23.51% of the total. The total number of shareholders has decreased to 31,420, indicating potential consolidation or exits among retail investors. The gradual decline in FII participation over recent quarters, from 0.72% in March 2023 to 0.33% in September 2025, may raise concerns about international investor confidence. Conversely, the increase in DII holdings from 1.16% in December 2022 to 3.66% in September 2025 suggests growing institutional interest, which could provide a stabilizing effect on the stock price. Overall, the shareholder distribution reflects a primarily domestically-driven investor base with significant promoter confidence.
Outlook, Risks, and Final Insight
Looking ahead, Gufic BioSciences is well-positioned to leverage its growth trajectory, supported by a strong product pipeline and increasing sales. However, the company faces several risks, including rising operational costs and a high cash conversion cycle that could impact liquidity. The increasing interest expenses, which rose to ₹25 Cr for March 2025, pose a risk to profitability if not managed effectively. Furthermore, the declining net profit and EPS figures in recent quarters could affect investor sentiment. Should the company successfully address its efficiency challenges and maintain revenue growth, it can further enhance shareholder value. Conversely, if operational inefficiencies persist, it may hinder profitability and investor confidence. Gufic BioSciences must navigate these dynamics carefully to sustain its market position and capitalize on growth opportunities in the pharmaceutical sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 214/84.3 | 27.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,631 Cr. | 424 | 479/192 | 95.9 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.1 Cr. | 39.7 | 40.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,853.93 Cr | 1,159.04 | 53.64 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 175 | 177 | 173 | 195 | 215 | 202 | 195 | 203 | 204 | 208 | 205 | 227 | 230 |
| Expenses | 142 | 143 | 141 | 160 | 176 | 165 | 161 | 167 | 166 | 174 | 178 | 195 | 195 |
| Operating Profit | 33 | 34 | 32 | 35 | 39 | 36 | 34 | 36 | 39 | 34 | 27 | 32 | 36 |
| OPM % | 19% | 19% | 19% | 18% | 18% | 18% | 18% | 18% | 19% | 16% | 13% | 14% | 16% |
| Other Income | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 2 |
| Interest | 2 | 2 | 3 | 4 | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 | 10 |
| Depreciation | 5 | 6 | 6 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 | 8 |
| Profit before tax | 27 | 27 | 24 | 28 | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 16 | 21 |
| Tax % | 26% | 25% | 24% | 26% | 25% | 25% | 26% | 26% | 26% | 26% | 26% | 26% | 27% |
| Net Profit | 20 | 20 | 18 | 21 | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 12 | 15 |
| EPS in Rs | 2.08 | 2.10 | 1.87 | 2.13 | 2.39 | 2.22 | 2.00 | 2.08 | 2.17 | 1.93 | 0.79 | 1.20 | 1.49 |
Last Updated: January 1, 2026, 1:46 pm
Below is a detailed analysis of the quarterly data for Gufic BioSciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 230.00 Cr.. The value appears strong and on an upward trend. It has increased from 227.00 Cr. (Jun 2025) to 230.00 Cr., marking an increase of 3.00 Cr..
- For Expenses, as of Sep 2025, the value is 195.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 195.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 36.00 Cr.. The value appears strong and on an upward trend. It has increased from 32.00 Cr. (Jun 2025) to 36.00 Cr., marking an increase of 4.00 Cr..
- For OPM %, as of Sep 2025, the value is 16.00%. The value appears strong and on an upward trend. It has increased from 14.00% (Jun 2025) to 16.00%, marking an increase of 2.00%.
- For Other Income, as of Sep 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Jun 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 10.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.00 Cr. (Jun 2025) to 10.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 8.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Jun 2025) to 21.00 Cr., marking an increase of 5.00 Cr..
- For Tax %, as of Sep 2025, the value is 27.00%. The value appears to be increasing, which may not be favorable. It has increased from 26.00% (Jun 2025) to 27.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Jun 2025) to 15.00 Cr., marking an increase of 3.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.49. The value appears strong and on an upward trend. It has increased from 1.20 (Jun 2025) to 1.49, marking an increase of 0.29.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:17 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 121 | 148 | 201 | 245 | 306 | 351 | 379 | 488 | 779 | 691 | 807 | 820 | 870 |
| Expenses | 109 | 134 | 181 | 222 | 267 | 305 | 327 | 404 | 631 | 556 | 657 | 683 | 741 |
| Operating Profit | 12 | 14 | 20 | 23 | 39 | 46 | 52 | 84 | 148 | 135 | 150 | 136 | 129 |
| OPM % | 10% | 10% | 10% | 9% | 13% | 13% | 14% | 17% | 19% | 20% | 19% | 17% | 15% |
| Other Income | 1 | 1 | 1 | 1 | 4 | 4 | 6 | 4 | 3 | 3 | -0 | 4 | 5 |
| Interest | 4 | 4 | 6 | 6 | 9 | 10 | 14 | 14 | 5 | 8 | 17 | 25 | 32 |
| Depreciation | 2 | 4 | 4 | 4 | 4 | 5 | 14 | 16 | 19 | 22 | 17 | 21 | 28 |
| Profit before tax | 6 | 7 | 10 | 14 | 30 | 35 | 30 | 58 | 127 | 107 | 116 | 94 | 74 |
| Tax % | 32% | 36% | 29% | 37% | 45% | 38% | 25% | 23% | 24% | 25% | 26% | 26% | |
| Net Profit | 4 | 4 | 7 | 9 | 16 | 22 | 23 | 44 | 96 | 80 | 86 | 70 | 54 |
| EPS in Rs | 0.55 | 0.54 | 0.95 | 1.17 | 2.13 | 2.82 | 2.92 | 5.68 | 9.89 | 8.22 | 8.59 | 6.97 | 5.41 |
| Dividend Payout % | 9% | 9% | 5% | 4% | 2% | 2% | 2% | 2% | 1% | 1% | 1% | 1% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 75.00% | 28.57% | 77.78% | 37.50% | 4.55% | 91.30% | 118.18% | -16.67% | 7.50% | -18.60% |
| Change in YoY Net Profit Growth (%) | 0.00% | 75.00% | -46.43% | 49.21% | -40.28% | -32.95% | 86.76% | 26.88% | -134.85% | 24.17% | -26.10% |
Gufic BioSciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 17% |
| 3 Years: | 2% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 25% |
| 3 Years: | -10% |
| TTM: | -29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 35% |
| 3 Years: | 16% |
| 1 Year: | -7% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 22% |
| 3 Years: | 18% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 5:30 am
Balance Sheet
Last Updated: December 4, 2025, 1:19 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 18 | 19 | 26 | 30 | 46 | 68 | 120 | 164 | 259 | 338 | 523 | 591 | 619 |
| Borrowings | 33 | 33 | 43 | 57 | 80 | 98 | 126 | 62 | 64 | 334 | 333 | 336 | 369 |
| Other Liabilities | 52 | 67 | 75 | 84 | 104 | 106 | 152 | 157 | 188 | 179 | 227 | 232 | 271 |
| Total Liabilities | 111 | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 | 1,093 | 1,170 | 1,268 |
| Fixed Assets | 30 | 25 | 22 | 22 | 23 | 24 | 83 | 100 | 115 | 160 | 159 | 506 | 495 |
| CWIP | 0 | 0 | 0 | 0 | 2 | 10 | 31 | 13 | 41 | 170 | 307 | 22 | 24 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 3 |
| Other Assets | 81 | 102 | 130 | 156 | 213 | 245 | 294 | 279 | 365 | 531 | 625 | 639 | 747 |
| Total Assets | 111 | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 | 1,093 | 1,170 | 1,268 |
Below is a detailed analysis of the balance sheet data for Gufic BioSciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 619.00 Cr.. The value appears strong and on an upward trend. It has increased from 591.00 Cr. (Mar 2025) to 619.00 Cr., marking an increase of 28.00 Cr..
- For Borrowings, as of Sep 2025, the value is 369.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 336.00 Cr. (Mar 2025) to 369.00 Cr., marking an increase of 33.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 271.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 232.00 Cr. (Mar 2025) to 271.00 Cr., marking an increase of 39.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,268.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,170.00 Cr. (Mar 2025) to 1,268.00 Cr., marking an increase of 98.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 495.00 Cr.. The value appears to be declining and may need further review. It has decreased from 506.00 Cr. (Mar 2025) to 495.00 Cr., marking a decrease of 11.00 Cr..
- For CWIP, as of Sep 2025, the value is 24.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 24.00 Cr., marking an increase of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 747.00 Cr.. The value appears strong and on an upward trend. It has increased from 639.00 Cr. (Mar 2025) to 747.00 Cr., marking an increase of 108.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,268.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,170.00 Cr. (Mar 2025) to 1,268.00 Cr., marking an increase of 98.00 Cr..
Notably, the Reserves (619.00 Cr.) exceed the Borrowings (369.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -21.00 | -19.00 | -23.00 | -34.00 | -41.00 | -52.00 | -74.00 | 22.00 | 84.00 | -199.00 | -183.00 | -200.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 85 | 82 | 102 | 78 | 97 | 107 | 103 | 93 | 71 | 109 | 149 | 140 |
| Inventory Days | 144 | 165 | 180 | 190 | 238 | 190 | 249 | 138 | 102 | 202 | 188 | 211 |
| Days Payable | 176 | 223 | 188 | 132 | 192 | 157 | 238 | 162 | 125 | 143 | 156 | 155 |
| Cash Conversion Cycle | 54 | 25 | 94 | 136 | 143 | 141 | 114 | 69 | 48 | 167 | 181 | 197 |
| Working Capital Days | 20 | 4 | 18 | 14 | 26 | 40 | 17 | 63 | 50 | 68 | 97 | 93 |
| ROCE % | 17% | 18% | 24% | 24% | 33% | 30% | 21% | 29% | 46% | 23% | 17% | 13% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Multicap Fund | 1,480,998 | 0.33 | 52.67 | N/A | N/A | N/A |
| SBI Healthcare Opportunities Fund | 1,000,000 | 0.86 | 35.57 | 1,000,000 | 2025-04-22 17:25:34 | 0% |
| ICICI Prudential Smallcap Fund | 446,517 | 0.19 | 15.88 | 441,293 | 2025-12-15 09:10:00 | 1.18% |
| Bank of India Small Cap Fund | 348,463 | 0.63 | 12.39 | N/A | N/A | N/A |
| ICICI Prudential ELSS Tax Saver Fund | 74,008 | 0.02 | 2.63 | N/A | N/A | N/A |
| ICICI Prudential Bharat Consumption Fund | 32,021 | 0.03 | 1.14 | 4,993 | 2025-12-15 09:10:00 | 541.32% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 1.00 | 1.00 |
| Basic EPS (Rs.) | 6.95 | 8.74 |
| Diluted EPS (Rs.) | 6.95 | 8.74 |
| Cash EPS (Rs.) | 9.05 | 10.29 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 59.94 | 53.11 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 59.94 | 53.11 |
| Revenue From Operations / Share (Rs.) | 81.75 | 80.44 |
| PBDIT / Share (Rs.) | 13.93 | 14.76 |
| PBIT / Share (Rs.) | 11.83 | 13.07 |
| PBT / Share (Rs.) | 9.39 | 11.54 |
| Net Profit / Share (Rs.) | 6.95 | 8.59 |
| NP After MI And SOA / Share (Rs.) | 6.95 | 8.59 |
| PBDIT Margin (%) | 17.04 | 18.35 |
| PBIT Margin (%) | 14.47 | 16.24 |
| PBT Margin (%) | 11.48 | 14.33 |
| Net Profit Margin (%) | 8.49 | 10.67 |
| NP After MI And SOA Margin (%) | 8.49 | 10.67 |
| Return on Networth / Equity (%) | 11.58 | 16.17 |
| Return on Capital Employeed (%) | 15.17 | 18.18 |
| Return On Assets (%) | 5.95 | 7.88 |
| Long Term Debt / Equity (X) | 0.21 | 0.28 |
| Total Debt / Equity (X) | 0.51 | 0.59 |
| Asset Turnover Ratio (%) | 0.72 | 0.00 |
| Current Ratio (X) | 1.61 | 1.61 |
| Quick Ratio (X) | 1.05 | 1.08 |
| Inventory Turnover Ratio (X) | 3.93 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 1.43 | 1.12 |
| Dividend Payout Ratio (CP) (%) | 1.10 | 0.93 |
| Earning Retention Ratio (%) | 98.57 | 98.88 |
| Cash Earning Retention Ratio (%) | 98.90 | 99.07 |
| Interest Coverage Ratio (X) | 5.70 | 9.64 |
| Interest Coverage Ratio (Post Tax) (X) | 3.84 | 6.61 |
| Enterprise Value (Cr.) | 3655.21 | 3142.92 |
| EV / Net Operating Revenue (X) | 4.46 | 3.90 |
| EV / EBITDA (X) | 26.16 | 21.23 |
| MarketCap / Net Operating Revenue (X) | 4.12 | 3.52 |
| Retention Ratios (%) | 98.56 | 98.87 |
| Price / BV (X) | 5.61 | 5.33 |
| Price / Net Operating Revenue (X) | 4.12 | 3.52 |
| EarningsYield | 0.02 | 0.03 |
After reviewing the key financial ratios for Gufic BioSciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.74 (Mar 24) to 6.95, marking a decrease of 1.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.74 (Mar 24) to 6.95, marking a decrease of 1.79.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.05. This value is within the healthy range. It has decreased from 10.29 (Mar 24) to 9.05, marking a decrease of 1.24.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 59.94. It has increased from 53.11 (Mar 24) to 59.94, marking an increase of 6.83.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 59.94. It has increased from 53.11 (Mar 24) to 59.94, marking an increase of 6.83.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 81.75. It has increased from 80.44 (Mar 24) to 81.75, marking an increase of 1.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.93. This value is within the healthy range. It has decreased from 14.76 (Mar 24) to 13.93, marking a decrease of 0.83.
- For PBIT / Share (Rs.), as of Mar 25, the value is 11.83. This value is within the healthy range. It has decreased from 13.07 (Mar 24) to 11.83, marking a decrease of 1.24.
- For PBT / Share (Rs.), as of Mar 25, the value is 9.39. This value is within the healthy range. It has decreased from 11.54 (Mar 24) to 9.39, marking a decrease of 2.15.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.59 (Mar 24) to 6.95, marking a decrease of 1.64.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.59 (Mar 24) to 6.95, marking a decrease of 1.64.
- For PBDIT Margin (%), as of Mar 25, the value is 17.04. This value is within the healthy range. It has decreased from 18.35 (Mar 24) to 17.04, marking a decrease of 1.31.
- For PBIT Margin (%), as of Mar 25, the value is 14.47. This value is within the healthy range. It has decreased from 16.24 (Mar 24) to 14.47, marking a decrease of 1.77.
- For PBT Margin (%), as of Mar 25, the value is 11.48. This value is within the healthy range. It has decreased from 14.33 (Mar 24) to 11.48, marking a decrease of 2.85.
- For Net Profit Margin (%), as of Mar 25, the value is 8.49. This value is within the healthy range. It has decreased from 10.67 (Mar 24) to 8.49, marking a decrease of 2.18.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.49. This value is within the healthy range. It has decreased from 10.67 (Mar 24) to 8.49, marking a decrease of 2.18.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.58. This value is below the healthy minimum of 15. It has decreased from 16.17 (Mar 24) to 11.58, marking a decrease of 4.59.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.17. This value is within the healthy range. It has decreased from 18.18 (Mar 24) to 15.17, marking a decrease of 3.01.
- For Return On Assets (%), as of Mar 25, the value is 5.95. This value is within the healthy range. It has decreased from 7.88 (Mar 24) to 5.95, marking a decrease of 1.93.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 0.28 (Mar 24) to 0.21, marking a decrease of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.51. This value is within the healthy range. It has decreased from 0.59 (Mar 24) to 0.51, marking a decrease of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.72. It has increased from 0.00 (Mar 24) to 0.72, marking an increase of 0.72.
- For Current Ratio (X), as of Mar 25, the value is 1.61. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.61.
- For Quick Ratio (X), as of Mar 25, the value is 1.05. This value is within the healthy range. It has decreased from 1.08 (Mar 24) to 1.05, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.93. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 3.93, marking an increase of 3.93.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 20. It has increased from 1.12 (Mar 24) to 1.43, marking an increase of 0.31.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 1.10. This value is below the healthy minimum of 20. It has increased from 0.93 (Mar 24) to 1.10, marking an increase of 0.17.
- For Earning Retention Ratio (%), as of Mar 25, the value is 98.57. This value exceeds the healthy maximum of 70. It has decreased from 98.88 (Mar 24) to 98.57, marking a decrease of 0.31.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 98.90. This value exceeds the healthy maximum of 70. It has decreased from 99.07 (Mar 24) to 98.90, marking a decrease of 0.17.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.70. This value is within the healthy range. It has decreased from 9.64 (Mar 24) to 5.70, marking a decrease of 3.94.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.84. This value is within the healthy range. It has decreased from 6.61 (Mar 24) to 3.84, marking a decrease of 2.77.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,655.21. It has increased from 3,142.92 (Mar 24) to 3,655.21, marking an increase of 512.29.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.46. This value exceeds the healthy maximum of 3. It has increased from 3.90 (Mar 24) to 4.46, marking an increase of 0.56.
- For EV / EBITDA (X), as of Mar 25, the value is 26.16. This value exceeds the healthy maximum of 15. It has increased from 21.23 (Mar 24) to 26.16, marking an increase of 4.93.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.12. This value exceeds the healthy maximum of 3. It has increased from 3.52 (Mar 24) to 4.12, marking an increase of 0.60.
- For Retention Ratios (%), as of Mar 25, the value is 98.56. This value exceeds the healthy maximum of 70. It has decreased from 98.87 (Mar 24) to 98.56, marking a decrease of 0.31.
- For Price / BV (X), as of Mar 25, the value is 5.61. This value exceeds the healthy maximum of 3. It has increased from 5.33 (Mar 24) to 5.61, marking an increase of 0.28.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.12. This value exceeds the healthy maximum of 3. It has increased from 3.52 (Mar 24) to 4.12, marking an increase of 0.60.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gufic BioSciences Ltd:
- Net Profit Margin: 8.49%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.17% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.58% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.84
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 61.3 (Industry average Stock P/E: 53.64)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.51
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.49%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 37, First Floor, Kamala Bhavan II, Mumbai Maharashtra 400069 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Jayesh P Choksi | Chairman & Managing Director |
| Mr. Pranav J Choksi | WholeTime Director & CEO |
| Mr. Pankaj J Gandhi | Whole Time Director |
| Dr. Anu S Auora | Independent Director |
| Mr. Kamal K Seth | Independent Director |
| Mr. Akshya Kumar Mahapatra | Independent Director |
FAQ
What is the intrinsic value of Gufic BioSciences Ltd?
Gufic BioSciences Ltd's intrinsic value (as of 08 January 2026) is ₹378.31 which is 13.95% higher the current market price of ₹332.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,330 Cr. market cap, FY2025-2026 high/low of ₹486/285, reserves of ₹619 Cr, and liabilities of ₹1,268 Cr.
What is the Market Cap of Gufic BioSciences Ltd?
The Market Cap of Gufic BioSciences Ltd is 3,330 Cr..
What is the current Stock Price of Gufic BioSciences Ltd as on 08 January 2026?
The current stock price of Gufic BioSciences Ltd as on 08 January 2026 is ₹332.
What is the High / Low of Gufic BioSciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gufic BioSciences Ltd stocks is ₹486/285.
What is the Stock P/E of Gufic BioSciences Ltd?
The Stock P/E of Gufic BioSciences Ltd is 61.3.
What is the Book Value of Gufic BioSciences Ltd?
The Book Value of Gufic BioSciences Ltd is 62.7.
What is the Dividend Yield of Gufic BioSciences Ltd?
The Dividend Yield of Gufic BioSciences Ltd is 0.03 %.
What is the ROCE of Gufic BioSciences Ltd?
The ROCE of Gufic BioSciences Ltd is 13.2 %.
What is the ROE of Gufic BioSciences Ltd?
The ROE of Gufic BioSciences Ltd is 12.3 %.
What is the Face Value of Gufic BioSciences Ltd?
The Face Value of Gufic BioSciences Ltd is 1.00.